Head to head
Abbott Laboratories vs Medtronic
Side-by-side on the measures that matter, with a plain-English read. Full detail: ABT · MDT
ABT
Abbott Laboratories
99.60+1.13%
1-year price shape — -24% over the period
Quant Rating D · 16/100
vs
MDT
Medtronic
88.48+0.83%
1-year price shape — -6% over the period
Quant Rating D · 31/100
1-year performance, rebased to 100
Medtronic edges it on the scoreable measures. Medtronic has the highest Quant Rating (31); Medtronic has done best over the past year (-6%); Medtronic trades cheapest on trailing earnings.
| ABT | MDT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 99.60 | 88.48 |
| Change today | +1.13% | +0.83% |
| 1-year return | -23.6% | -6.0% |
| Market cap | $172.35B | $113.18B |
| 52-week range | 81.39 – 130.33 | 72.06 – 102.92 |
| Valuation | ||
| P/E (TTM) | 32.23 | 21.79 |
| P/E percentile, own 5-yr range | 62nd | 5th |
| P/B | 3.37 | 2.25 |
| Dividend yield | 2.45% | 3.22% |
| Profitability & growth | ||
| EPS (TTM) | 3.72 | 3.73 |
| Net profit (TTM) | $6.44B | $4.77B |
| Revenue (TTM) | $46.59B | $37.54B |
| Revenue growth (YoY) | +13.0% | +13.7% |
| Gross margin | 56.6% | 65.0% |
| Operating margin | 15.8% | 19.0% |
| Net margin | 11.6% | 13.9% |
| Free cash flow (TTM) | $7.82B | $6.13B |
| Ownership & sentiment | ||
| Institutional ownership | 81.1% | 87.3% |
| Insider activity (12mo) | 36 buy / 12 sell | 28 buy / 17 sell |
| Short interest (% of float) | 0.8% | 3.1% |
| Analyst consensus | 100% buy (14) | 53% buy / 47% hold (19) |
| Analyst price target | $126 (+26%) | $103 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | D (16) | D (31) |
| Company | ||
| Employees | 115,000 | 95,000 |
| Founded | 1888 | 2014 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.